198 related articles for article (PubMed ID: 36884302)
1. Dabrafenib, alone or in combination with trametinib, in BRAF V600-mutated pediatric Langerhans cell histiocytosis.
Whitlock JA; Geoerger B; Dunkel IJ; Roughton M; Choi J; Osterloh L; Russo M; Hargrave D
Blood Adv; 2023 Aug; 7(15):3806-3815. PubMed ID: 36884302
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric
Bouffet E; Geoerger B; Moertel C; Whitlock JA; Aerts I; Hargrave D; Osterloh L; Tan E; Choi J; Russo M; Fox E
J Clin Oncol; 2023 Jan; 41(3):664-674. PubMed ID: 36375115
[TBL] [Abstract][Full Text] [Related]
3. Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory
Hargrave DR; Terashima K; Hara J; Kordes UR; Upadhyaya SA; Sahm F; Bouffet E; Packer RJ; Witt O; Sandalic L; Kieloch A; Russo M; Cohen KJ;
J Clin Oncol; 2023 Nov; 41(33):5174-5183. PubMed ID: 37643378
[TBL] [Abstract][Full Text] [Related]
4. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF
Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B
Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064
[TBL] [Abstract][Full Text] [Related]
5. Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma.
Si L; Zhang X; Shin SJ; Fan Y; Lin CC; Kim TM; Dechaphunkul A; Maneechavakajorn J; Wong CS; Ilankumaran P; Lee DY; Gasal E; Li H; Guo J
Eur J Cancer; 2020 Aug; 135():31-38. PubMed ID: 32534242
[TBL] [Abstract][Full Text] [Related]
6. Dabrafenib plus Trametinib in Pediatric Glioma with
Bouffet E; Hansford JR; Garrè ML; Hara J; Plant-Fox A; Aerts I; Locatelli F; van der Lugt J; Papusha L; Sahm F; Tabori U; Cohen KJ; Packer RJ; Witt O; Sandalic L; Bento Pereira da Silva A; Russo M; Hargrave DR
N Engl J Med; 2023 Sep; 389(12):1108-1120. PubMed ID: 37733309
[TBL] [Abstract][Full Text] [Related]
7. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
Planchard D; Besse B; Groen HJM; Souquet PJ; Quoix E; Baik CS; Barlesi F; Kim TM; Mazieres J; Novello S; Rigas JR; Upalawanna A; D'Amelio AM; Zhang P; Mookerjee B; Johnson BE
Lancet Oncol; 2016 Jul; 17(7):984-993. PubMed ID: 27283860
[TBL] [Abstract][Full Text] [Related]
8. Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.
Dhillon S
Target Oncol; 2016 Jun; 11(3):417-28. PubMed ID: 27246822
[TBL] [Abstract][Full Text] [Related]
9. Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II).
Atkinson V; Sandhu S; Hospers G; Long GV; Aglietta M; Ferrucci PF; Tulyte S; Cappellini GCA; Soriano V; Ali S; Poprach A; Cesas A; Rodriguez-Abreu D; Lau M; de Jong E; Legenne P; Stein D; King B; van Thienen JV
Melanoma Res; 2020 Jun; 30(3):261-267. PubMed ID: 31895752
[TBL] [Abstract][Full Text] [Related]
10. Dabrafenib plus trametinib in patients with previously untreated BRAF
Planchard D; Smit EF; Groen HJM; Mazieres J; Besse B; Helland Å; Giannone V; D'Amelio AM; Zhang P; Mookerjee B; Johnson BE
Lancet Oncol; 2017 Oct; 18(10):1307-1316. PubMed ID: 28919011
[TBL] [Abstract][Full Text] [Related]
11. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
Long GV; Flaherty KT; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Chiarion-Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JBAG; Hansson J; Utikal J; Ferraresi V; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; Davies MA; Lane SR; Legos JJ; Mookerjee B; Grob JJ
Ann Oncol; 2017 Jul; 28(7):1631-1639. PubMed ID: 28475671
[TBL] [Abstract][Full Text] [Related]
12. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.
Diamond EL; Subbiah V; Lockhart AC; Blay JY; Puzanov I; Chau I; Raje NS; Wolf J; Erinjeri JP; Torrisi J; Lacouture M; Elez E; Martínez-Valle F; Durham B; Arcila ME; Ulaner G; Abdel-Wahab O; Pitcher B; Makrutzki M; Riehl T; Baselga J; Hyman DM
JAMA Oncol; 2018 Mar; 4(3):384-388. PubMed ID: 29188284
[TBL] [Abstract][Full Text] [Related]
13. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
Flaherty KT; Infante JR; Daud A; Gonzalez R; Kefford RF; Sosman J; Hamid O; Schuchter L; Cebon J; Ibrahim N; Kudchadkar R; Burris HA; Falchook G; Algazi A; Lewis K; Long GV; Puzanov I; Lebowitz P; Singh A; Little S; Sun P; Allred A; Ouellet D; Kim KB; Patel K; Weber J
N Engl J Med; 2012 Nov; 367(18):1694-703. PubMed ID: 23020132
[TBL] [Abstract][Full Text] [Related]
14. Safety of combining dabrafenib plus trametinib in elderly BRAF V600 mutation-positive advanced melanoma patients: real-world data analysis of Spanish patients (ELDERLYMEL).
González-Barrallo I; Castellón Rubio VE; Medina J; España S; Mujika K; Majem M; Aguado C; Cabrera Suárez MÁ; Palacio I; Osterloh L; Martínez-Fernández A; García-Castaño A
Melanoma Res; 2022 Oct; 32(5):343-352. PubMed ID: 35762583
[TBL] [Abstract][Full Text] [Related]
15. Adverse Event Management in Patients with
Chalmers A; Cannon L; Akerley W
Oncologist; 2019 Jul; 24(7):963-972. PubMed ID: 30598499
[TBL] [Abstract][Full Text] [Related]
16. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.
Subbiah V; Kreitman RJ; Wainberg ZA; Cho JY; Schellens JHM; Soria JC; Wen PY; Zielinski CC; Cabanillas ME; Boran A; Ilankumaran P; Burgess P; Romero Salas T; Keam B
Ann Oncol; 2022 Apr; 33(4):406-415. PubMed ID: 35026411
[TBL] [Abstract][Full Text] [Related]
17. Dabrafenib plus trametinib in patients with BRAF
Subbiah V; Lassen U; Élez E; Italiano A; Curigliano G; Javle M; de Braud F; Prager GW; Greil R; Stein A; Fasolo A; Schellens JHM; Wen PY; Viele K; Boran AD; Gasal E; Burgess P; Ilankumaran P; Wainberg ZA
Lancet Oncol; 2020 Sep; 21(9):1234-1243. PubMed ID: 32818466
[TBL] [Abstract][Full Text] [Related]
18. Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for
Dummer R; Long GV; Robert C; Tawbi HA; Flaherty KT; Ascierto PA; Nathan PD; Rutkowski P; Leonov O; Dutriaux C; Mandalà M; Lorigan P; Ferrucci PF; Grob JJ; Meyer N; Gogas H; Stroyakovskiy D; Arance A; Brase JC; Green S; Haas T; Masood A; Gasal E; Ribas A; Schadendorf D
J Clin Oncol; 2022 May; 40(13):1428-1438. PubMed ID: 35030011
[TBL] [Abstract][Full Text] [Related]
19. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring
Odogwu L; Mathieu L; Blumenthal G; Larkins E; Goldberg KB; Griffin N; Bijwaard K; Lee EY; Philip R; Jiang X; Rodriguez L; McKee AE; Keegan P; Pazdur R
Oncologist; 2018 Jun; 23(6):740-745. PubMed ID: 29438093
[TBL] [Abstract][Full Text] [Related]
20. Dabrafenib Versus Dabrafenib + Trametinib in
Busaidy NL; Konda B; Wei L; Wirth LJ; Devine C; Daniels GA; DeSouza JA; Poi M; Seligson ND; Cabanillas ME; Sipos JA; Ringel MD; Eisfeld AK; Timmers C; Shah MH
Thyroid; 2022 Oct; 32(10):1184-1192. PubMed ID: 35658604
[No Abstract] [Full Text] [Related]
[Next] [New Search]
